News

Stentys said that the self-expanding feature of the platform is designed to ensure optimal apposition of a stent in the critical initial hours and days after an acute

The company has reported a net loss of $1,433,922, or ($0.11) per share, compared with a net loss of $11,852,152, or ($1.12) per share. Opexa has posted an

SecureTrace is a syndicate of 10 companies in the UK that are using technology to fight counterfeiting and diversion of pharmaceuticals throughout the supply chain. The project, according

Taro said that its fluorouracil cream is a prescription pharmaceutical product used for topical treatment of multiple actinic or solar keratoses and superficial basal cell carcinomas, and is

NerPharMa manufactures CTI’s drug pixantrone and has found the site in compliance and acceptable for continued manufacturing of the drug product. CTI has a New Drug Application (NDA)

For over four years, Post-Op Px has integrated tissue, clinical and molecular information to enable physicians and their patients to make more informed decisions about post-surgical, adjuvant therapies.

The MicroPhage’s instrument-free, rapid tests are based on its patented Bacteriophage Amplification platform technology. The company has also begun OUS commercial shipments of the test. MicroPhage’s initial commercial

The Pancreas, Biliary and Liver Surgery Center is under the leadership of Dr Michael Wayne, Dr Franklin Kassim and Dr Avram Cooperman. Under the terms of the agreement,

Menarini said that it is planning to launch other drugs shortly, notably in UK, Germany and Ireland. Thierry Poiraud, general manager of Menarini in France, said: “We are